Login to Your Account



Making the Case for Arikace

TOBI or Not? Insmed Doubters Relax, $58M Raise for CF Push

By Randy Osborne
Staff Writer

Thursday, July 18, 2013
Investor disappointment earlier this month regarding positive – but apparently not positive enough – Phase III results with Insmed Inc.'s antibiotic candidate seemed to be turning around on word that the company is netting $58 million in a stock sale to help push Arikace to the finish line.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription